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compounds [8]. In animals, the irreversible kinase inhibi-
tors were found to have increased antitumor effects,
suggesting that destruction, not solely inactivation, of
Her2 might have an enhanced therapeutic effect [9].
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Henri Huezo, Maria Vilenchik, Neal Rosen,
and Gabriela Chiosis*
Program in Cell Biology and
Department of Medicine
Memorial Sloan-Kettering Cancer Center
1275 York Avenue kinases involves targeting hsp90 with agents that inter-
fere with its chaperone function. Hsp90 activity can beNew York, New York 10021
inhibited with agents that bind to its N-terminal ATP/
ADP pocket, such as geldanamycin (GM), radicicol (RD),
and the novel inhibitors PU3 and PU24FCl [10–14] orSummary
agents that bind to a C-terminal pocket, such as novobi-
ocin [15]. Addition of these agents to cells induces theOverexpression of the transmembrane tyrosine ki-
proteasomal degradation of a small subset of proteinsnases Her2 and EGFR is associated with aggressive
involved in signal transduction, such as steroid recep-malignancies, and several therapeutic strategies tar-
tors, Raf1 kinase, and certain transmembrane tyrosinegeting the two receptors are now in various stages of
kinases such as Her2 and EGFR [10–15]. FK228, a depsi-clinical development. Most of the known agents block
peptide that acetylates hsp90, also causes Her2 degra-the activation or inhibit the activity of the kinases;
dation [16]. Thus, agents that target hsp90 through di-however, a more significant therapeutic outcome may
verse mechanisms can cause destruction of Her2 andresult from degrading these oncoproteins. Here, we
EGFR.report the development of a microtiter cell-based
Identification of new agents that induce the degrada-assay that sensitively detects cellular levels of Her2
tion of Her2 and EGFR could lead to novel therapeuticand EGFR. The assay is useful in identifying small mol-
strategies. However, to our knowledge there are no re-ecules that alter cellular levels of these kinases and
ported assays that can detect cellular levels of Her2 andin quantifying their effect. The method gives results
EGFR in high-throughput format.comparable to Western blot, but it is faster, less labor
A miniaturized whole-cell immunodetection assayintensive, and amenable to high throughput.
was reported by Schreiber et al. [17]. They demonstrated
the use of this assay to monitor biosynthetic processes,
Introduction such as DNA synthesis, and posttranslational pro-
cesses, such as acetylation and phosphorylation. The
Human carcinomas frequently express high levels of assay sensitively detected changes in specific cellular
transmembrane tyrosine kinases in the human epider- macromolecules in mammalian cells and is compatible
mal growth factor receptor (Her) family, and overexpres- with screening large numbers of small molecules in
sion of at least two of these, Her1 (EGFR) and the closely nanoliter to microliter culture volumes.
related Her2, is associated with a more aggressive clini- Here, we modify and extend the use of this technique
cal behavior [1–3]. Transfection or activation of high to the development of a fast, cell-based assay that en-
levels of these two receptors in nonmalignant cell lines ables the quantitative analysis of intracellular levels of
can lead to a transformed phenotype [4, 5]. The impor- Her2 and EGFR. We refer to these assays as Her2 blot
tance of the Her-receptor family in tumor pathogenesis and EGFR blot, respectively, and apply them to identify
and progression suggests that agents that interfere with and quantify the potency of small molecules in altering
their function may have significant therapeutic activity cellular levels of these kinases.
[6]. Monoclonal antibodies (MAbs) that block activation
of the EGFR and Her2 have been developed. Trastuzu-
mab (Herceptin), a humanized anti-Her2 MAb, has clini- Results and Discussion
cal activity and was recently approved for use in patients
with advanced breast cancer with high levels of Her2. To identify agents that alter the cellular levels of two of
IMC-C225, a chimeric anti-EGFR MAb, has shown activ- the Her-family members, Her2 and EGFR, we developed
ity in combination with chemotherapy or radiation. In a microtiter cell-based assay that is a hybrid Western
addition to antibodies, compounds that directly inhibit blotting and enzyme-linked immunosorbent assay
the receptor tyrosine kinase activity of Her2 and EGFR (ELISA). The method consists of plating cells in microti-
have shown preclinical and clinical activity [7]. ters and treating them with small molecules at equal
Recently, it has been shown that some of the irrevers- concentration to identify agents that alter cellular levels
ible Her2 tyrosine kinase inhibitors enhance ubiquityla- of the kinases or varying concentrations of the same
tion and accelerate endocytosis with subsequent intra- compound to determine the potency of the agent in
cellular destruction of Her2 molecules. The degradative degrading the protein. Following treatment, cells are
pathway stimulated by these agents is mediated by fixed and permeabilized with MeOH. An antibody
chaperones and is common to the hsp90-interfering against Her2 or EGFR is added, followed by a secondary
antibody linked to horseradish peroxidase (HRP). Upon
addition of a luminescence substrate, the signal emitted*Correspondence: chiosisg@mskcc.org
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is read in a luminometer. The signal of treated and un-
treated cells is quantified, allowing calculation of IC50
values (concentration of drug where 50% of total Her2/
EGFR was degraded).
Assay Development for Use in 96-Well Plates
Antibody Optimization
The success of such an assay requires identification
of optimal combinations of cell number, primary and
secondary antibodies, blocking and washing buffers.
We screened a panel of primary and secondary antibod-
ies searching for a reasonable signal to noise ratio and
found the combination of two antibodies obtained form
Santa Cruz Biotechnology, the anti-Her2 SC-284, a rab-
bit polyclonal antibody that binds to the carboxyl termi-
nus region of the protein, and the anti-rabbit SC-2004
to perform excellently in the Her2-blot assay (entry 3,
Figure 1A). The signal resulting from specific antibody
binding (white bars, Figure1A) was significantly greater
than nonspecific antibody binding to the plate (black
bars, Figure 1A) or cells (gray bars, Figure 1A). For EGFR,
the best signal was obtained with the rabbit polyclonal
antibody 06-847 from Upstate Biotechnology (entries
1 and 2, Figure 1B). Interestingly, the best performing
antibodies in the Her2 and EGFR blot also work well in
Western blot assays.
Cell Number Optimization Figure 1. Antibodies Screened for Best Signal/Noise Ratio
Experiments were performed with SKBr3, a breast can-
(A) SKBr3 cells and (B) A431 cells were treated for 24 hr with vehicle.
cer cell line that expresses high levels of Her2, and Cells were fixed and permeabilized, and the Her2 blot (A) or EGFR
A431, a vulvar cancer line with EGFR overexpression. blot (B) reagents were added. Each column represents the lumines-
cence reading obtained from the combination of a primary and aAs expected, the signal in untreated cells increased with
secondary antibody. Columns: 1, Ab1  Sec1; 2, Ab2  Sec2; 3,increasing cell number; however, the ratio of signal over
Ab2  Sec1; 4, Ab2  Sec2; etc. For Her2: Ab1  Transductionbackground (S/B) reached a plateau at approximately
Laboratories E19420, mouse IgG2b, epitope  N-terminal domain;8000 plated cells/well (Figure 2A). A significant S/B value
Ab2  Santa Cruz SC-284, rabbit polyclonal, epitope  carboxyl
was obtained using a minimum 1000 cells/well (S/B  terminus; Ab3  Oncogene OP39, mouse IgG1, epitope  extracel-
20); however, the calculated Z value [18] at this cell lular domain; Ab4  NeoMarkers MS-267, mouse monoclonal,
epitope extracellular domain; Ab 5NeoMarkers MS-301, mousenumber was of a borderline value (Z  0.46). Cell plating
monoclonal, epitope  extracellular domain; Ab6  Oncogenenumbers above 1000 cells/well were considered useful
OP16, mouse IgG2a, epitope  extracellular domain; Ab7  Neo-in a screening assay, the recorded Z values and S/B
Markers MS-599, epitope  C terminus. For EGFR: Ab1  Upstateratios being higher than 0.5 or at least 25, respectively.
Biotechnology 06-847, rabbit polyclonal IgG, epitope  C-terminal
We believed satisfactory plating to be a number of ap- domain; Ab2  Upstate Biotechnology 06-129, sheep polyclonal
proximately 3000 cells/well for SKBr3 and approxi- IgG, epitope  cytoplasmic domain; Ab3  Upstate Biotechnology
05-104, mouse monoclonal IgG, epitope  Ala351-Asp364; Ab4 mately 2000 cells/well for A431. A time interval of 48 hr
BD Pharmingen, mouse IgG; Ab5NeoMarkers MS-269-P1, mousebetween plating and assay was used to attain a good
monoclonal, epitope  extracellular domain; Ab6  Calbiochemattachment and confluency of the cells in the well.
PC19, rabbit polyclonal IgG. When Ab is rabbit, Sec1  Santa CruzMicroplate Optimization
SC-2004 and Sec2  Sigma A0545. When Ab is mouse, Sec1 
Adequate S/B ratios (30) were obtained using Corning Amersham NXA931 and Sec2  Sigma A9044. When Ab is sheep,
black, clear bottom plates and Perkin Elmer white, clear Sec1  Sigma A3415 and Sec2  Upstate Biotechnology 12-342.
Blank is a measure of unspecific binding of the primary and second-bottom plates. Paradoxically, the Corning white, clear
ary antibodies to the plate. IgG control represents the reading ob-bottom plates gave higher background readings, and
tained by addition to cells of a normal IgG and the correspondingalthough the signal was additionally high, the maximum
HRP-linked secondary antibody.S/B value was only 14. Thus, preference was given to
Corning black, clear bottom plates, and all data pre-
sented here were recorded in such plates. of compounds. The variability in the obtained signal of
the Her2 blot is due to the fact that all reagents were
manually added and would likely be diminished withAssay Test
Z Values automatization. Even with the introduction of human
error, a Z value of 0.7 is obtained, a value consideredA good signal window is essential for hit identification
in a HTS assay. Variations associated with vehicle-only excellent for a screening assay (Figure 2B).
Reproducibility of Datatreated cells and background IgG measurements are
taken in account by the Z coefficient. The Z parameter To test the practicability of our conditions and the accu-
racy of the Her2/EGFR blot, we tested several agentsis a characteristic of the assay itself, without intervention
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Figure 2. Assay Optimization and Performance
(A) SKBr3 cells were left to attach for the indicated time period prior to Her2-blot analysis. The signal recorded in anti-Her2 (S) and IgG (B)
reacted wells was recorded, and the ratio S/B was plotted as a function of cell number. Each measurement represents the average of eight
wells.
(B) Results of Z analysis in the Her2 blot. SKBr3 cells were reacted with the anti-Her2 antibody (open circles; std  7.5%), the corresponding
IgG (solid squares; std  16.8%), and 20 hsp90 inhibitors (at 30 M) from an in-house library (solid triangles) [13, 14].
whose action on Her2 and EGFR was either reported in SKBr3 cells induces the degradation of Her2 with an
IC50 value of 4 M (Figure 3A). The values obtainedliterature or analyzed in our group by immunoblotting
(Western blot). It was determined that addition of an with GM and RD were 17 nM and 28 nM, respectively
(data not shown), consistent with prior literature reportshsp90 inhibitor to SKBr3 cancer cells induced the rapid
proteasomal degradation of Her2, most protein being [11, 12]. The assay was also performed after a 6 hr drug
treatment to again reproduce data obtained by Westerndepleted at 6 hr [11] (data not shown). Degradation of
EGFR occurs with different kinetics; considerable ef- blot (data not shown).
To rule out that the declining signal in drug-treatedfects on EGFR in the A431 cell line are observed only at
12 hr [19] (data not shown). To observe maximal protein cells was not the result of reduced cell number caused
by unspecific cell death but to decreased Her2 content,depletion, a 24 hr drug treatment was considered more
appropriate. The time frame, however, can be set to an we determined the amount of total protein by the bicin-
choninic assay (BCA) [20] and also tested changes ininterval that best suits the purpose of the screening
assay. -actin protein levels. We found the BCA assay to be
compatible with the Her2-blot reagents. Two 96-wellIC50 values for Her2 degradation obtained by our
method were compared to Western blot analysis results. plates were treated with various concentrations of
PU24FCl: the first was subjected to a BCA assay alone,The hsp90 inhibitor, PU24FCl, and the natural products
GM and RD gave values in the Her2-blot method identi- and the second was subjected to a Her2 blot experiment
followed by a BCA assay (Figure 4A). Measured differ-cal to the Western blot assay. Addition of PU24FCl to
Figure 3. Reproducibility and Robustness of the Her2 and EGFR Blots
(A) SKBr3 cells and (B) A431 cells were treated with various concentrations of PU24FCl for 24 hr in 10 cm plates for Western blot and 96-
well plates for Her2/EGFR blot. Her2 or EGFR content was quantified by each method and plotted versus drug concentration. Values obtained
from three Her2 blot and EGFR blot experiments conducted on various plates and time intervals are plotted (p 0.1). All values were normalized
for total protein content. The Western blot data represent the average of three experiments. In the Her2 blot/EGFR blot assays, drugs were
added to quadruplicate wells.
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Figure 5. Testing of the Her2 Blot in a Library Screening Format
SKBr3 cells were treated with 20 hsp90-interacting agents [13, 14]
(at 30 M) for 6 hr. The Her2-level-reducing effect of the agents was
compared to vehicle-only-treated cells (DMSO). Each measurement
is an average of eight wells. The average signal obtained for these
agents (in RLU) is plotted in Figure 2B (solid triangles).
were indeed due to a selective reduction in oncoprotein
levels. If, however, variation in total protein content is
observed, values obtained for Her2 can be normalized
to total protein concentration. Both the BCA assay and
-actin blot are compatible with the Her2 blot and can be
performed following Her2 quantification. It is noteworthy
that actin-level measurements could be indicative of the
antiproliferative effect of the tested compounds. Thus,
in addition to identifying changes in Her2, screening
would be indicative of cytotoxic effects of the com-
pounds.
Stability of the Assay
The Her2-blot assay signal is stable and the obtained
values are reproducible from plate-to-plate and day-to-
Figure 4. Specificity of the Her2 Blot day measurements. PU24FCl was used as a test com-
SKBr3 cells were treated for 24 hr in two 96-well plates with either pound on several plates at different time periods (Figure
vehicle or increasing concentrations of PU24FCl. Cells were fixed 3A). The curves obtained in separate readings of this
and permeabilized. compound were overlapping (IC50s of 4.00, 4.18, and(A) Total protein concentration was determined using the BCA assay
4.54; standard deviation of 6%).without prior manipulations in the first plate (gray bars) and subse-
PU24FCl was also tested in the A431 cell line to deter-quently to the Her2 blot in the second plate (white bars). Black
mine the feasibility of the assay in quantifying EGFRbars depict Her2 protein levels determined by the Her2 blot. Each
measurement is an average of six wells. Control, vehicle-only treated depletion. Using Western blot and EGFR blot, an IC50
cells. value for EGFR degradation of approximately 25 M
(B) Changes in -actin levels were determined upon addition of was observed. As with the Her2 blot, the EGFR blot was
drug without prior manipulations in the first plate (white bars) and
robust, with data obtained by the method reproduciblesubsequently to the Her2 blot in the second plate (gray bars).
over several plates (Figure 3B).
Assay Test in Library Screen Formatences in total protein between the two plates were insig-
nificant, and an average of 1.5–1.6 g protein was de- The data presented validate the capability of the assay
to quantify the effects of agents that decrease cellulartected in each well. We additionally monitored possible
changes in -actin levels due to drug addition, prior to levels of Her2 or EGFR. We further used the assay in a
library screen format to identify agents capable of alter-and following the Her2 blot (Figure 4B). If the -actin
blot was performed subsequent to the Her2 blot, plates ing the cellular levels of these kinases. A subset of our
hsp90-inhibitor library [14] was added to SKBr3 cells atwere stripped and blocked for nonspecific binding prior
to the addition of an anti-actin antibody. As expected, a set concentration of 30 M, and the ability of these
agents to decrease Her2 levels in cells was determinedthe levels of actin in the stripped plate were slightly
diminished but detectable. Thus, this method, similar after a 6 hr treatment (Figure 5 and Figure 2B). Agents
that alter cellular levels of kinase by at least 25%–30%to Western blot, allows for reblotting of the plate. No
significant differences in actin expression were seen can be considered “hits” with a high degree of confi-
dence (Figure 2B). There was no significant change inbetween untreated and Her2-depleted cells, validating
the observation that the lower Her2 levels in treated cells total protein content as determined by the BCA assay;
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ice-cold Tris buffer saline (TBS) containing 0.1% Tween 20 (TBST)thus, the values reflect the effect of these compounds
(200 l). A house vacuum source attached to an eight-channel aspi-on Her2 expression.
rator was used to remove the liquid from the microplates. Further,It is noteworthy that identical activity in the series of
methanol (100 l at 20	C) was added to each well, and the plate
compounds was previously obtained using the tradi- was left at 4	C for 10 min. Methanol was removed by washing with
tional Western blot [14]; however, this work required a TBST (2 
 200 l). The plate was further incubated at RT for 1 hr
with SuperBlock (Pierce 37535) (200 l) and overnight at 4	C withthree-week period.
the anti-Her-2 antibody (Santa Cruz Biotechnology SC-284) (100 l,The presented technique has advantages over tradi-
1:200 in SuperBlock). Each well was washed with TBST (2 
 200tional Western blot methods in that it is faster and less
l) and incubated at RT for 2 hr with an anti-rabbit HRP-linkedlabor intensive. On the negative side, the assay cannot
antibody (Sigma A0545) (100 l, 1:1000 in SuperBlock). Unreacted
differentiate between full-length Her kinase and cleav- antibody was removed by washing with TBST (3 
 200 l), and the
age fragments that would be easily distinguishable on chemiluminescent substrate solution (100 l) (Pierce 38040) was
added. The plate was read 5 min later in an Analyst AD plate readerWestern blot, as fragments would run differently.
(Molecular Devices). Each well was scanned for 0.1 s. Readings
from wells containing only control IgG and the corresponding HRP-Significance
linked secondary antibody were set as background and deducted
from all measured values. Luminescence readings resulted from
Given the important role of the Her receptor family in drug-treated cells versus untreated cells (vehicle treated) were
the pathogenesis and progression of cancer, agents quantified and plotted against drug concentration to give the IC50
values (defined as concentration of drug required to degrade 50%that interfere with their activity could have an impor-
of total Her2).tant role in the treatment of cancer patients. Mono-
Other anti-Her2 antibodies tested were purchased from Transduc-clonal antibodies that block the activation of the ki-
tion Laboratories (E19420), NeoMarkers (MS-267, MS-301, MS-599),
nases or small molecules that inhibit their function are and Oncogene (OP16, OP39). Another anti-rabbit-HRP antibody was
now in different stages of clinical trial or are already purchased from Santa Cruz Biotechnology (SC-2004), and the anti-
in clinical use. These agents do not induce significant mouse-HRP antibodies were purchased from Amersham (NXA931)
and Sigma (A9044). Normal rabbit and mouse IgGs were purchasedkinase degradation, and it is believed that decreasing
from Santa Cruz Biotechnology (SC-2027 and SC-2025).cellular levels of these kinases may result in a greater
clinical activity. We now report a cell-based microtiter-
EGFR Blotformat method for identifying and quantifying agents
The experiment was conducted identically as for Her2. The anti-that alter cellular levels of Her2 and EGFR. Given that
EGFR antibody used was purchased from Upstate Biotechnology
this assay uses cells and a nonhomogeneous ELISA- (06-847) and was used 1:500 in SuperBlock. Other anti-EGFR anti-
type readout, it is applicable to high throughput. New bodies tested were purchased from Upstate Biotechnology (06-129,
agents that induce the degradation of Her2 and EGFR 05-104), Santa Cruz Biotechnology (SC-03-G), NeoMarkers (MS-
269-P1), BD Pharmingen (610016), and Calbiochem (PC19). The anti-can thus be identified by screening large libraries of
sheep HRP-linked antibodies and the normal sheep IgG were pur-compounds using this assay format. Considering the
chased from Sigma (A3415), Upstate Biotechnology (12-342), andpotential clinical importance of these agents, this fast
Santa Cruz Biotechnology (SC-2717), respectively.
and reliable assay may aid new drug development ef-
forts.
Actin Blot
If the assay was performed previous to the Her2 or EGFR-blots, the
Experimental Procedures experiment was conducted as described for the Her2 blot. The anti-
-actin antibody was purchased from Sigma (AC15) and was used
Cell Culture 1:5000 in SuperBlock. The secondary antibody was purchased from
The human cancer cell lines SKBr3 and A431 were obtained from the Amersham (NXA931) and used 1:10,000 in SuperBlock. If the assay
American Type Culture Collection (Manassas, VA) and maintained in was performed consequently to the Her2 blot, the plates were
1:1 mixture of DME:F12 supplemented with 2 mM glutamine, 50 washed with TBST (2 
 200 l) and stripped with Pierce Stripping
units/ml penicillin, 50 units/ml streptomycin, and 5% heat-inacti- Buffer (Pierce 21059) (100 l) for 10 min at room temperature.
vated fetal bovine serum (FBS) (Gemini Bioproducts) and incubated
at 37	C in 5% CO2. Stock culture was grown in T-175 flasks con-
Total Proteintaining 30 ml DME (HG, F-12, nonessential amino acids, and penicil-
Total protein content was determined using the bicinchoninic acidlin and streptomycin) with glutamine and 10% FBS. Cells were disso-
(BCA) reagent (Pierce 23225). Plates resulting from Her2/EGFR blotciated with 0.05% trypsin and 0.02% EDTA in phosphate buffer
readings were washed with TBST (2 
 200 l) and incubated withsaline (PBS) without calcium and magnesium.
the BCA reagent (150 l) for 30 min at 37	C. Protein concentrationGM was obtained from the Developmental Therapeutics Program/
was determined using a standard solution of bovine serum albuminNational Cancer Institute, while RD was purchased from Sigma-
(BSA). Absorbance was read using a Spectra Max Plus microplateAldrich. The synthesis of PU24FCl and the purine-based hsp90 li-
spectrophotometer (Molecular Devices).brary was described elsewhere [13, 14]. All drug stocks were made
in DMSO.
Protein Assays
Cells were grown to 60%–70% confluence and exposed to drugs orHer2 Blot
Experimental cultures were plated in black, clear-bottom microtiter DMSO vehicle for the indicated time periods. Lysates were prepared
using 50 mM Tris (pH 7.4), 0.1% NP-40 lysis buffer. Protein concen-plates (Corning 3603) (3000 cells per well for SKBr3 and 2000 cells
per well for A431) in growth medium (100 l) and allowed to attach tration was determined using the BCA kit (Pierce 23225) according
to the manufacturer’s instructions. Clarified protein lysates (20–50for at least 48 hr at 37	C and 5% CO2. Some wells were left without
cells to serve as the blank. Growth medium (100 l) with drug or g) were electrophoretically resolved on denaturing SDS-PAGE,
transferred to nitrocellulose, and probed with anti-Her2 (C-18) (Santavehicle (DMSO) was carefully added to the wells, and the microtiter
plates were placed at 37	C and 5% CO2. DMSO levels should not Cruz Biotechnology SC-284) or anti-EGFR (Upstate Biotechnology
06-847) followed by the corresponding HRP-linked secondary anti-exceed 0.1% (higher levels were found to affect the growth of cancer
cells). body. Blots were visualized by autoradiography, and the protein
was quantified using BioRad Gel Doc 1000 software. The IC50 wasFollowing incubation (6 hr or 24 hr), wells were washed twice with
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calculated as the drug concentration needed to degrade 50% of Hsp90 and shares important biologic activities with geldana-
mycin. Cancer Chemother. Pharmacol. 42, 273–279.the total protein.
12. Schulte, T.W., Akinaga, S., Soga, S., Sullivan, W., Stensgard,
B., Toft, D., and Neckers, L.M. (1998). Antibiotic radicicol bindsData Analysis
to the N-terminal domain of Hsp90 and shares important bio-Statistical analysis was performed using the Analysis Tool Pack
logic activities with geldanamycin. Cell Stress Chaperones 2,provided in Microsoft Excel. To detect differences between data
100–108.sets, a Student’s t test (2-tailed) was applied. Values for which p 
13. Chiosis, G., Timaul, M.N., Lucas, B., Munster, M.N., Zheng, F.F.,0.15 were considered significant.
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